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Abstract
The expression and activity of P-glycoprotein (pGP)
play a role in the multidrug resistance of tumors. Be-
cause solid-growing tumors often show pronounced
hypoxia or extracellular acidosis, this study attempted
to analyze the impact of an acidic environment on the
expression and activity of pGP and on the cytotoxicity
of chemotherapeutic agents. For this, prostate carci-
noma cells were exposed to an acidic extracellular en-
vironment (pH 6.6) for up to 24 hours. pGP activity
was more than doubled after 3 to 6 hours of incuba-
tion in acidic medium, whereas cellular pGP expres-
sion remained constant, indicating that increased
transport rate is the result of functional modulation.
In parallel, the cytotoxic efficacy of daunorubicin
showed pronounced reduction at low pH, an effect that
was reversible on coincubation with a pGP inhibitor.
A reduction of intracellular Ca2+ concentration by 35%
under acidic conditions induced a higher transport rate
of pGP, an effect comparable to that found on inhibition
of protein kinase C (PKC). These data indicate that pGP
activity is increased by acidic pH presumably as a result
of lowered intracellular calcium levels and inhibition of
PKC.These findingsmayexplain the reducedcytotoxicity
of chemotherapeutic agents in hypoxic/acidic tumors.
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Introduction
Solid-growing tumors differ profoundly from normal tissues
with respect to morphologic and histopathological features
and also in terms of physiological characteristics at the cel-
lular and tissue levels. These functional parameters include
properties of microcirculation, interstitial transport, oxygen
and substrate supply, extracellular pH, and bioenergetic
status [1]. These factors are closely linked and form a com-
plex network, the so-called metabolic microenvironment. As
a result of numerous functional and structural abnormalities
in the tumor vascular network, the metabolic microenviron-
ment of tumors is fundamentally different from that found in
normal tissues [1]. Consequently, the mean oxygen partial
pressure (pO2) in tumors is often considerably lower than
that in surrounding normal tissues. Approximately 60% of
human tumors show severe hypoxia or even anoxia in vital
tumor tissues [2]. Because of insufficient O2 delivery, tumor
cells undergomarked changes in their metabolic pathways. The
cells switch to glycolysis (a phenomenon that can also occur
in tumors even when oxygen supply is sufficient—known as the
Warburg effect), leading to the accumulation of high levels
of lactate and low glucose concentrations. Simultaneously,
many tumors exhibit pronounced extracellular acidity with pH
values that are, in some instances, even lower than 6.5 [1].
Data that have been available for several years suggest
that hypoxia in solid tumors is one of the major reasons for the
limited efficacy of several nonsurgical treatment modalities,
such as sparsely ionizing radiation [3,4] or photodynamic ther-
apy [5]. Additionally, several cell culture studies have shown
various chemotherapeutic agents to be more effective in the
presence of oxygen [6–8]. In in vivo experiments, Teicher et al.
[9] showed the antineoplastic activity of several drugs in experi-
mental sarcomas of mice to be correlated with tumor perfusion.
The authors assumed that well-perfused tissue areas corre-
sponded to normoxic regions, whereas poorly perfused regions
indicated hypoxic tissues. They found that several chemo-
therapeutic agents (including cyclophosphamide, carboplatin,
andmelphalan) induced amore pronounced cell kill in ‘‘oxygen-
ated’’ tumor areas than in ‘‘hypoxic’’ regions, indicating possible
O2 sensitivity of these drugs. Grau and Overgaard [10], using
in vivo experiments, showed that 5-fluorouracil or methotrex-
ate had a cytotoxic effect only on well-oxygenated, but not on
hypoxic, tumors. Various possible direct or indirect (through
acidification of extracellular space) reasons for these differ-
ences have been discussed (for a review, see Ref. [11]): 1)
oxygen might directly influence the mechanism of action (phar-
macodynamics) of antineoplastic drugs (e.g., alkylating agents)
[12]; 2) hypoxia can cause cell cycle arrest and in turn reduce
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the efficacy of agents acting only on proliferating cells [12,13];
and 3) hypoxic tissues show pronounced extracellular acid-
ity [1], which might influence intracellular/extracellular drug
distribution and in turn lead to a reduced intracellular concen-
tration of chemotherapeutic agents [13–15].
In addition, several tumor cell lines (as well as cells from
numerous normal tissues) have active transport mecha-
nisms through which drugs are moved out of the cells. Trans-
port proteins, which belong to the ATP-binding cassette
(ABC) transporter family, can carry different chemothera-
peutic agents [e.g., daunorubicin (DNR), paclitaxel, vincris-
tine, and many others] and may therefore be responsible
for chemoresistance seen in a number of tumors (multidrug
resistance, MDR) [16,17]. In the field of clinical oncology,
one important member of the ABC transporter family is P-
glycoprotein (pGP; a product of the MDR1 gene) [18,19]. In-
hibition of this transporter has been seen to increase the
cytotoxic efficacy of several chemotherapeutic agents [20].
Besides constitutional differences in the pGP expression
of tumor entities or cell lines, the expression as well as the
functional activity of the transporter have been shown to
be regulated. Cytokines [interleukin (IL) 1b, IL-6, and tumor
necrosis factor a (TNF-a)] and growth factors (epidermal
growth factor, EGF) are known to be capable of altering the
functional activity of pGP [21,22].
When these results are considered, a question arises: Do
microenvironmental parameters affect the transport efficacy
of pGP? Only a small number of studies have analyzed the
impact of the microenvironment on pGP expression. Hyp-
oxia [23], glucose depletion [24], and reactive oxygen spe-
cies [25] have been shown to be capable of regulating the
MDR1 gene. However, the impact of the microenvironment
on the functional activity of pGP still remains unclear.
The aim of this study was to analyze whether extracellu-
lar pH (a parameter of the metabolic microenvironment) in tu-
mors affects the activity or expression of pGP and whether
pH has an impact on the cytotoxic efficacy of chemothera-
peutic drugs through the modulation of pGP transport rate.
In addition, the study attempted to clarify which intracellular
mechanisms might be involved in such a regulation of pGP
activity by the metabolic microenvironment.
Materials and Methods
Materials
pGP antibody (clone C219) was purchased from Signet
Laboratories (Dedham, MA), and the secondary antibody [rab-
bit anti-mouse, horseradish peroxidase (HRP)–conjugated]
was from BioTrend (Cologne, Germany). Ionomycin was ob-
tained from MP-Biomedicals (Irvine, CA). All other chemicals
were purchased from Sigma-Aldrich (Taufkirchen, Germany).
Cell Line
The subline AT1 of the rat R-3327 Dunning prostate car-
cinoma was used in all experiments. This cell line is known to
functionally express pGP [26]. Cells were grown in RPMI
medium supplemented with 10% fetal calf serum (FCS) at
37jC under a humidified 5% CO2 atmosphere and passaged
once per week. For the experiments, cells grew either in Petri
dishes (2.5  106 to 3.0  106 cells) or in 96-well plates (4 
104 to 5  104 cells). For the experiments, cells were trans-
ferred to RPMI medium without additional FCS supplemen-
tation 24 hours prior to the measurements. For control
experiments, the medium was buffered with 20 mM HEPES
adjusted to pH 7.4. For acidic conditions, cells were incu-
bated in a medium buffered with 20 mM morpholinoethane-
sulfonic acid + 4.51 mM NaHCO3, which resulted in pH 6.6
for up to 24 hours.
Rhodamine-123 Efflux Assay
To assess the activity of pGP, the efflux rate of rhodamine-
123 in the presence or absence of a specific pGP inhibitor
(verapamil, VPL) was measured. For this, cells were incu-
bated with rhodamine (0.5 mM, dissolved in Ringer solution)
for 30 minutes at 37jC. Subsequently, the rhodamine-
containing solution was removed, and the cells were rapidly
washed with phosphate-buffered saline (PBS) at 4jC and
then incubated with fresh rhodamine-free Ringer solution.
Samples (100 ml) of the supernatant were taken at 0, 5, 15,
and 45 minutes after medium exchange. Rhodamine-123
efflux rate could then be calculated from the increase in
rhodamine-123 concentration in the Ringer solution, as de-
termined by fluorimetric measurements using a fluorescence
microplate reader (Victor2; Wallac, Turku, Finland) with exci-
tation/emission wavelengths of 485/535 nm. To determine
pGP-mediated efflux rate, a second set of cells was primarily
incubated with rhodamine-123, as described above; how-
ever, thereafter, the solution was replaced by rhodamine-free
Ringer solution containing VPL (10 mM, dissolved in EtOH).
Due to the inhibition of pGP by VPL, the rhodamine efflux
rate was slower. The ratio of the efflux rate with and without
VPL was used as a measure of the activity of pGP-mediated
efflux [21].
As a second measure of pGP activity, intracellular
rhodamine-123 concentration in the presence or absence of
VPL was determined. For this, cells were treated as described
above (30 minutes of incubation with 0.5 mM rhodamine so-
lution, then the medium was changed to rhodamine-free so-
lution with and without 10 mM VPL). After 45 minutes, cells
were washed and lysed with Triton X-100. The intracellular
rhodamine-123 concentration of the lysate was determined
fluorimetrically at excitation/emission wavelengths of 485/
535 nm. The ratio of the intracellular rhodamine concentration
with and without VPL was used as a measure of pGP activity.
All measurements were normalized to the protein con-
tent in each Petri dish determined with bicinchoninic acid
(BCA) assay (Pierce, KMF Laborchemie, SanktAugustin,
Germany), as described previously [27].
pGP Expression
The cellular expression of pGP was determined in whole-
cell enzyme-linked immunosorbent assay, as described
previously [28]. In brief, after cell fixation with 4% paraformal-
dehyde for 60 minutes, cells were washed with a permeabil-
izing buffer containing 0.1% Triton X-100 and then incubated
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for 20 minutes with this buffer, to which 0.6% H2O2 had been
added. After incubation with the primary anti-pGP antibody
(diluted 1:1000) at 4jC overnight, cells were washed and in-
cubated with a secondary anti-mouse peroxidase antibody
(diluted 1:1000) for 1 hour. Thereafter, cells were incubated
with an HRP substrate (containing 0.5 mg/ml o-phenylenedi-
amine, 11.8 mg/ml Na2HPO42H2O, 7.3 mg/ml citric acid,
and 0.015% H2O2) for 15 minutes and measured photo-
metrically at a wavelength of 490 nm using a microplate
reader (Victor2; Wallac). To normalize pGP expression for
the number of cells in each well, permeabilized cells were
subsequently incubated with 0.2% trypan blue solution for
5 minutes, washed with PBS, and dissolved with 1% so-
dium dodecyl sulfate, and the trypan blue concentration as
a measure of cell number was determined photometrically.
Intracellular pH Measurement
Intracellular pH was determined using the pH-sensitive
fluorescent dye 2V,7V-bis-(2-carboxyethyl)-5(6)-carboxyfluo-
rescein (BCECF), as described previously by Weiner and
Hamm [29]. In brief, 3.0  105 to 3.5  105 cells were incu-
bated on coverslips with BCECF (final concentration, ap-
proximately 2 mM) for 5 minutes at 37jC. Subsequently, the
coverslips were transferred to an inverse microscope (Axio-
vert 100 TV; Zeiss, Oberkochen, Germany). Excitation wave-
length was switched between 460 and 488 nm. Emission
fluorescence was monitored at 535 nm using a charge-
coupled device (CCD) camera system (C4742-95; Hama-
matsu Photonics, Herrsching, Germany) and image analysis
software (Aquacosmos ver. 1.3; Hamamatsu Photonics).
After subtraction of background levels, the fluorescence in-
tensity ratio at both excitation wavelengths was calculated
every 10 seconds. At the end of each measurement pe-
riod, pH calibration was performed. For this, two calibration
solutions containing 132 mM KCl, 10 mM NaCl, 1 mM CaCl,
1 mM MgCl, 10 mM HEPES, and 10 mM nigericin were
prepared and adjusted to pH 6.8 and 7.6, respectively. The
cells were superfused with these solutions, and fluorescence
ratio was measured. The intracellular pH of each cell was
calculated from linear interpolation of calibration points.
Intracellular Ca2+ Concentration
Cytosolic free Ca2+ ([Ca2+]in) was determined using the
Ca2+-sensitive fluorescent dye Fura-2, as described by
Grynkiewicz et al. [30]. In brief, 3.0  105 to 3.5  105 cells
were incubated on coverslips with Fura-2 (final concentra-
tion, 5 mM) for 15 minutes at 37jC. Thereafter, the coverslips
were transferred to an inverse microscope, and fluorescence
was measured at 535 nm whereas excitation wavelength
was switched between 334 and 380 nm. The fluorescence
intensity of each cell was monitored with a CCD camera
system, and the fluorescence intensity ratio at both excitation
wavelengths (FL340/FL380) was calculated every 5 seconds.
[Ca2+]in was calculated according to Grynkiewicz et al. [30],
assuming a dissociation constant (Kd) of 225 nM. At the end
of each measurement period, Ca2+ calibration was performed
with two calibration solutions, each containing 141 mM NaCl,
0.8 mM NaH2PO4, 3.2 mM Na2HPO4, 4 mM KCl, and 1 mM
ionomycin. One calibration solution additionally contained
1 mM CaCl2, whereas the other one was rendered Ca
2+-free
by the addition of 1 mMEGTA. The cells were superfused with
these solutions, and fluorescence ratios (Rmin and Rmax) were
measured. With these values, intracellular Ca2+ concentra-
tion was calculated according to the formula described in
Grynkiewicz et al. [30].
Caspase 3 Activity and Cell Toxicity Assay
To assess the cytotoxic activity of DNR (which is a sub-
strate of pGP) and cisplatin (which is not transported by
pGP) [19,26] under different conditions, the relative caspase
3 activity normalized with respect to untreated control cells
and the repopulation of cells 42 hours after chemotherapy
were measured. For these experiments, cells were grown
as a confluent monolayer (2.5  106 to 3.0  106 cells per
Petri dish). Cells were incubated with serum-free medium
24 hours prior to commencement of chemotherapy. Three
hours before the application of chemotherapeutic drugs, cells
were exposed to either acidic (pH 6.6) or control medium
(pH 7.4). Subsequently, cells were incubated with DNR (final
concentration, 10 mM) or cisplatin (final concentration,
150 mM) for 3 hours at 37jC, whereby acidic or control con-
ditions were maintained. After this period of time, the medium
was replaced again. For caspase 3 activity measurements,
cells were exposed to serum-free control medium (pH 7.4) for
a further 3 hours, after which caspase 3 activity was mea-
sured as described below. For repopulation experiments,
the medium was replaced following incubation with chemo-
therapeutic drugs with FCS-containing control medium, and
cells were maintained under normal cell culture conditions
for 42 hours. Thereafter, the cell concentration in the Petri
dishes was determined using an automatic cell counter (Z2;
Coulter, Krefeld, Germany). In a second series of experi-
ments designed to assess the impact of pGP activity on
DNR toxicity, cells were incubated with DNR solution addi-
tionally containing the pGP inhibitor VPL (final concentration,
10 mM; dissolved in EtOH). Caspase 3 activity and repopu-
lation were performed analogously to the first series, as de-
scribed above.
Caspase 3 activity was determined as described pre-
viously [31] using a caspase 3 activity kit (Clontech Labo-
ratories, Heidelberg, Germany), in accordance with the
manufacturer’s instructions. For this, cells were incubated
with a lysis buffer (100 ml) for 20 minutes on ice, harvested,
and centrifuged at 16,000g for 10 minutes at 4jC. The su-
pernatant (60 ml) was incubated with the caspase 3 substrate
DEVD-AFC (60 ml; to give a final concentration of 40 mM) at
37jC in a 96-well plate. The fluorescence of the cleaved prod-
uct AFC was measured at 405 nm excitation wavelength and
535 nm emission wavelength using a fluorescencemicroplate
reader (Victor2; Wallac). Cleaved AFC was quantified with a
calibration curve using known AFC concentrations. All mea-
surements were normalized with respect to the protein con-
tent in each probe.
Necrosis formation was quantified by the assessment of
lactate dehydrogenase (LDH) release from cells into the me-
dium. The activity of LDH in media and cell lysates was
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determined in an automatic analyzer (Cobas-Mira; Roche
Diagnostics, Mannheim, Germany).
Statistical Analysis
Results are expressed as mean ± standard error of the
mean (SEM). Differences between groups were assessed
by two-tailed Wilcoxon test for unpaired samples. The sig-
nificance level was set at a = 5% for all comparisons.
Results
In rat R-3327-AT1 prostate carcinoma cells, a reduction of ex-
tracellular pH to a value of 6.6 (Figure 1C) for up to 6 hours
resulted in a significant increase in pGP-mediated rhodamine-
123 efflux rate as measured by the ratio of the efflux rates
in the absence and presence of the inhibitor VPL (Figure 1A).
When cells were kept under acidic environmental condi-
tions for 3 to 6 hours, relative pGP activity was more than
doubled. After this time, the activity returned to control levels.
This has also been shown by measurements of intracellular
rhodamine-123 concentration in the presence or absence
of the inhibitor VPL. Under control conditions (pH 7.4), intra-
cellular concentration was approximately 1.7-fold higher
when pGP transport was inhibited compared to values
obtained without VPL (Table 1). Maintaining the cells in an
acidic environment for 3 to 6 hours led to a significant in-
crease in this concentration ratio (Table 1), indicating a higher
pGP activity. Because the cellular expression of pGP pro-
tein was not markedly altered by an acidic environment
(Figure 1B), the increase in the rhodamine efflux rate must
result from either an increase in the functional activity of
pGP or a translocation of preformed transporters to the cell
membrane. Due to the increased activity of the pGP trans-
porter, it seems likely that the intracellular concentration of
chemotherapeutic drugs is reduced (which, in rhodamine
efflux experiments, resulted in a lower intracellular rhodamine
concentration; data not shown).
The cytotoxicity of DNR (which is a substrate of pGP)
and cisplatin (which is known not to be transported by this
pump) [19] was reduced by the acidic environment. With cis-
platin, caspase 3 activity was significantly reduced compared
to normal pH (Figure 2A). However, even though cisplatin-
induced caspase 3 activation was markedly reduced in the
acidic environment, overall cell kill (as measured by the num-
ber of surviving tumor cells) was not significantly different
in cells incubated with cisplatin at different pH levels. These
results indicate that the cytotoxicity of cisplatin was only
marginally affected by the acidic environment. This may be
the result of an increase in necrosis formation measured by
LDH release into the medium. With cisplatin treatment at
pH 7.4, 5 ± 2% of the total LDH was found in the medium,
whereas at pH 6.6, this fraction increased significantly to
33 ± 12%. DNR-induced caspase 3 activation was markedly
reduced by the acidic environment, reaching approximately
Figure 1. (A) Activity of pGP (described by the ratio of rhodamine-123 efflux rates in the presence or absence of VPL, respectively) and (B) relative pGP expression
in AT1 cells kept under acidic conditions for up to 24 hours. (C) Extracellular pH during this period. Values at t = 0 hour were measured at pH 7.47 (pretreatment pH
of normal cell culture medium) after which the medium was changed to pH 6.6. Values are expressed as mean ± SEM. *P < .05; n, number of experiments.
Table 1. Ratio of Intracellular Rhodamine-123 Concentration in the Pres-
ence and Absence of the pGP Inhibitor VPL (10 MM) in AT1 Cells Maintained
under Acidic Conditions for Up to 24 Hours.
Time under Acidic
Conditions (h)
n Rhodamine-123
Concentration Ratio
0 12 1.72 ± 0.16
3 12 2.97 ± 0.28**
6 12 2.43 ± 0.26*
12 12 1.82 ± 0.15
24 12 1.81 ± 0.27
Values are expressed as mean ± SEM.
n, number of experiments.
*P < .05 vs t = 0 hour.
**P < .01 vs t = 0 hour.
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the same level as that found in nontreated cells (Figures 2A
and3A). In parallel, the number of surviving tumor cells 42hours
after chemotherapy was significantly higher (Figures 2B and
3B). The results presented in Figures 2 and 3 show differ-
ences between individual absolute values for both caspase 3
activity and cell concentration. Because the results were ob-
tained in two independent experimental series, different mea-
sured values reflect interexperimental variation. To determine
whether the effect seen with DNR was the result of increased
pGP activity, VPL was added. Under acidic conditions, cas-
pase 3 activity was significantly increased compared to DNR
treatment alone (Figure 3A). A higher caspase 3 activity
(indicating a higher apoptosis rate) was also evident in the
lower number of surviving tumor cells (Figure 3B).
To study the underlying mechanisms by which extracel-
lular pH may influence pGP activity, changes in intracellular
pH and Ca2+ concentration were measured (Figure 4). On
exposure of the cells to an acidic medium (i.e., a decline in
extracellular pH from 7.4 to 6.6), intracellular pH fell to 6.3
within 10 minutes. After the return of the medium back to
pH 7.4, intracellular pH also returned to control values. Intra-
cellular Ca2+ concentration also changed markedly when
the extracellular pH was lowered. Within the first minute,
[Ca2+]in declined by approximately 45% of the initial value
and recovered partially by 10% within 10 minutes. When the
pH of the medium returned to normal, the Ca2+ concentration
also increased, returning to control levels within a few min-
utes (Figure 4). Similar changes in intracellular Ca2+ concen-
tration can also be obtained by reducing extracellular Ca2+
from its control level (1.2 mM) to low values (0.005 mM),
whereby intracellular Ca2+ concentration was reduced by
approximately 50% (Figure 5A). Under these environmental
conditions, relative pGP activity was more than doubled
(Figure 5B) and is comparable to levels obtained under an
acidic extracellular environment (Figure 1A). These results
indicate that intracellular Ca2+ level may play an important
Figure 2. Cytotoxic activity of DNR (10 M) and cisplatin (150 M) measured by (A) the drug-induced caspase 3 activity and (B) the repopulation of tumor cells
42 hours after chemotherapy under acidic (pH 6.6) and control (pH 7.4) conditions. Values are expressed as mean ± SEM of five experiments. *P < .05.
Figure 3. Cytotoxic activity of DNR (10 M) measured by (A) the DNR-induced caspase 3 activity and (B) the repopulation of tumor cells 42 hours after
chemotherapy under acidic (pH 6.6) and control (pH 7.4) conditions. In addition, the impact of pGP inhibition by VPL (10 M) on DNR cytotoxicity under these
conditions is shown. Values are expressed as mean ± SEM of five experiments. *P < .05.
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role in the regulation of pGP activity. Under acidic conditions,
[Ca2+]in is markedly reduced so that a subsequent increase in
pGP activity is observed.
One possible mechanism by which intracellular Ca2+ con-
centration may affect pGP-mediated drug efflux is through an
alteration of protein kinase C (PKC) activity. To test this
hypothesis, the impact of the inhibition or activation of PKC
on pGP activity was assessed. Inhibition of the PKC by
bisindolylmaleimide I (BIM) led to doubling of the pGP-
mediated rhodamine-123 efflux, whereas activation of the
PKC by phorbol 12–myristate 13–acetate (PMA) practically
had no effect (Figure 6).
Discussion
The impact of an acidic extracellular environment on the drug
transport rate of pGP and the consequences of such con-
ditions on the cytotoxic efficacy of chemotherapeutic drugs
were investigated in this study. For this, R3327-AT1 prostate
carcinoma was used, a cell line that shows a strong expres-
sion of pGP, predominantly on the cell membrane [32], indi-
cating that pGP in this cell line is functional [26,32]. These
cells were exposed to an extracellular pH of 6.6, a value that
has been reported to prevail in many human tumors [1]. As
a measure of transport activity, rhodamine-123 efflux was
measured at various times during incubation in an acidic
culture medium. A significant increase in transport rate (a
factor of 2–2.5) was observed when cells were exposed to
an acidic environment for 3 to 6 hours (Figure 1A). There-
after, pGP activity returned to control levels most probably
as a result of cellular damage incurred by low pH. After
24 hours of incubation under acidic conditions, many cells
became detached from the Petri dish. In vivo, tumor oxygen-
ation shows pronounced temporal fluctuations due to tem-
poral changes in tumor blood flow [33]. This results in periods
during which the extracellular space becomes acidic, which
Figure 4. Time course of intracellular pH (.) and intracellular Ca2+ concentration (D) after a rapid change of extracellular pH in the medium. Values are expressed
as mean ± SEM (n, number of cells investigated).
Figure 5. Impact of extracellular Ca2+ concentration on (A) intracellular Ca2+ concentration [Ca2+]in (n, number of cells investigated) and (B) on the activity of pGP
(described by the ratio of rhodamine-123 efflux rates in the presence or absence of VPL, respectively; n, number of experiments). Values are expressed as mean ±
SEM. *P < .05; **P < .001.
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alternate with periods during which a normal pH prevails. For
this reason, an elevation of pGP activity over even longer
times can be expected in vivo.
The higher efflux rate of pGP under acidic conditions
leads to a lower concentration of chemotherapeutic drugs
within the cell, as indicated by a higher fraction of intracellular
rhodamine-123 concentration in the presence or absence of
VPL (Table 1). Because cytotoxic efficacy is usually directly
correlated with intracellular drug concentration, a reduction
in the efficacy of chemotherapeutic agents that are sub-
strates of pGP is to be expected under acidic conditions. In
the present study, DNR-induced cytotoxicity was found to be
significantly reduced after cell incubation at pH 6.6, whereas
the cytotoxicity of cisplatin, which is not a pGP substrate,
was affected only to a minor extent (Figure 2A). The overall
cell kill with cisplatin was independent of extracellular pH
(Figure 2B). Herman et al. [34] found that, with decreasing pH
(from 7.4 to 6.45), cisplatin-induced cytotoxicity was mark-
edly increased in EMT6 mouse mammary carcinoma cells.
One possible explanation for the discrepancy between the
latter and the present study may be differences in the sen-
sitivity of the cell lines to cisplatin. A further reason could be
the high cisplatin dose used in the present study, which may
induce an almost maximal cytotoxic effect that cannot be
further amplified by low pH. However, in contrast to experi-
ments with DNR, a reduction of cell kill was not observed.
When DNR treatment was combined with VPL (a known
inhibitor of pGP), the cytotoxic effect under acidic conditions
was found to be restored almost to that of nonacidic cells
(Figure 3). These results support the notion of an increased
pGP activity being responsible for the reduced cytotoxicity of
DNR at acidic pH. The lack of impact of VPL on DNR cyto-
toxicity under nonacidic control conditions (Figure 3) might
be due to the fact that, at normal pH, DNR leads to an almost
maximal caspase 3 activation (possibly as a result of an al-
ready low pGP activity), which in turn results in a cell kill that
cannot be further enhanced by pGP inhibition.
Because anthracyclines are eliminated from the cells by
other transporters such as multidrug resistance–associated
protein 1 (MRP1), the observed effects of the acidic envi-
ronment may be the result of altered MRP1 activity or ex-
pression. To measure MRP1 activity, a similar efflux study
was performed as described for pGP. In this case, however,
calcein (0.1 mM) was used as a fluorescent MRP1 substrate,
and the transporter was inhibited by probenecid (2 mM). The
activity of the MRP1 was, however, found to be only margin-
ally increased (by a factor of 1.4 ± 0.2) when the cells were
incubated at an acidic pH for 3 to 6 hours (data not shown).
These results indicated that modulation of pGP activity plays
a much more important role in the effect of acidosis on DNR
cytotoxicity than modulation of MRP1 activity.
A higher transport rate could be: 1) due to an increase in
cellular pGP expression; 2) a higher activity of pre-existing
transporters; or 3) a translocation of preformed transporters
to the outer cell membrane (which might be the case with
pGP) [35,36]. Several parameters causing changes in the
tumor micromilieu, such as hyperthermia, glucose depletion,
reactive oxygen species, or hypoxia, have also been shown
to cause changes in pGP expression (with hypoxia possibly
resulting from an upregulation of the hypoxia-inducible fac-
tor HIF-1) [23–25,37,38]. In addition, exposure to chemo-
therapeutic drugs that are inhibitors of pGP or MRP1 (e.g.,
VPL, rifampicin) has been shown to induce pGP expression
[39]. Finally, cytokines (such as IL-6, IL-1b, or TNF-a) have
been shown to modulate pGP expression [21]. Even so, the
acidic extracellular pH applied in the present study had al-
most no effect on cellular pGP concentration (Figure 1B),
indicating that a higher transport rate seems to be predomi-
nantly the result of increased pump activity. Functional modu-
lation of pGP activity by metabolic parameters has been
discussed by other groups. Because the ABC transporter ac-
tively pumps substrates out of the cell, activity may depend
on the cellular ATP level, which serves as an energy source.
Because many solid-growing tumors show pronounced hyp-
oxia, tumor cells have to switch to the less effective meta-
bolic pathway of glycolysis, which results in a reduced yield
of ATP [1,40]. The inhibition of glycolysis has been pro-
posed as a possible therapeutic strategy to overcome drug
Figure 6. Impact of PKC inhibition by BIM (0.2 M) or activation by PMA (1 M) on the activity of pGP (described by the ratio of rhodamine-123 efflux rates in the
presence or absence of VPL). Values are expressed as mean ± SEM. *P < .05; n, number of experiments.
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resistance. Indeed, it has been shown that inhibition of mito-
chondrial respiration leads to an increase in the cytotoxic ef-
ficacy of various chemotherapeutic drugs probably due to
a reduced pGP activity, which in turn can be attributed to a
depletion of ATP [41]. In the present study, where cells were
exposed to acidic conditions under normoxia, glucose con-
centration in the medium was high even after 24 hours of in-
cubation (9.31 ± 0.15 mM; data not shown). For this reason,
depletion of ATP and subsequent inhibition of pGP activity
are not to be expected over the time span of the experiment.
In contrast, the rhodamine-123 efflux rate was more than
doubled when the cells were incubated at pH 6.6 (Figure 1A).
Besides microenvironmental factors, cytokines have also
been found to modulate pGP function. In a chemoresistant
cell line (MCF-7/AdrR) functionally expressing pGP, Yang
et al. [22] found that EGF increased pGP activity within
30 minutes, probably by phospholipase C activation. How-
ever, pGP phosphorylation by PKC has also been discussed
as a possibility of modulating pGP activity at a posttransla-
tional level [42,43]. Tsuruoka et al. [44] reported that activa-
tion of PKC by PMA can reduce the pGP-mediated drug
efflux rate. In the present study, PMA had almost no effect
on rhodamine-123 efflux, whereas the inhibition of PKC by
BIM led to a doubling of transport rate (Figure 6). PKC thus
obviously appears to play a role in the regulation of pGP
activity. PKC inhibition increases transport rate, whereas
PKC activation reduces it. The question arises as to whether
extracellular pH is able to modulate PKC activity and thereby
exert its influence on the pGP transport rate. Various mem-
brane receptors [e.g., ovarian cancer G-protein–coupled
receptor 1 (OGR1) [45] or T-cell death–associated gene
8 (TDAG8) [46]] have been shown to be capable of acting
as membrane-located proton sensors that use inositol phos-
phate as a second messenger. Through these receptors,
extracellular pH can directly affect intracellular signaling path-
ways. Because such a direct pH-sensing mechanism has not
been described for PKC, other possible signaling pathways
also need to be considered. Several PKC isoforms are Ca2+-
dependent, so that one possibility would be a change in the
intracellular free calcium concentration ([Ca2+]in). In the pres-
ent study, [Ca2+]in was found to be reduced by approximately
35%when cells were exposed to an acidicmedium (Figure 4).
A comparable reduction in intracellular calcium can be
obtained by reducing the extracellular Ca2+ concentration to
approximately 5 mM (Figure 5A). When this had been done
(pH 7.4, extracellular Ca2+ = 5 mM), pGP activity was more
than doubled, revealing the important role that intracellular
calcium concentration may play in the regulation of the pGP
transport rate. Low intracellular Ca2+ levels that have been
found in chemoresistant cell lines may also be indicative of
the impact of calcium in this context [47,48]. Grabowski et al.
[49] described the accumulation of etoposide in pGP-over-
expressing cells as being independent of intracellular free
calcium levels. However, the study only looked at the effects
of transient calcium changes and their blockage using a
BAPTA-AM pretreatment, whereas the impact of basal con-
centration was not examined.
From the findings of the present study, it seems probable
that intracellular Ca2+ concentration affects the pGP trans-
port rate, possibly through an alteration of PKC activity.
Based on our findings, we propose a model of mechanisms
by which an acidic extracellular environment may affect
pGP activity (Figure 7): extracellular acidosis leads to a
decrease of intracellular calcium concentration by approxi-
mately 35%. This decrease is comparable to that found when
extracellular calcium level is reduced to almost 0 mM. As a
result of reduced intracellular Ca2+, PKC activity will be
reduced, leading in turn to an increase in pGP activity. These
mechanismsmay explain the decrease of DNR-induced cyto-
toxicity, which can be restored by VPL through pGP inhibi-
tion (Figure 3).
Nevertheless, the question as to how extracellular pH can
influence intracellular Ca2+ level has not been answered
conclusively in this study. In Figure 4, intracellular pH can be
seen to decrease within 5 to 10 minutes following a lower-
ing of extracellular pH. Such intracellular acidosis has not
been described in vivo. Several studies have demonstrated
that the intracellular pH of solid-growing tumors remains
almost constant even if the extracellular pH becomes
strongly acidic (for a review, see Ref. [1]). In cell culture ex-
periments, however, a decrease in cellular pH parallel to the
medium pH similar to that found in the present study has
Figure 7. Model of the mechanisms by which an acidic extracellular microenvironment may affect pGP activity. ECS, extracellular space; ICS, intracellular space
(for details, see text).
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been described [50,51]. The discrepancy between in vivo
and in vitro findings is still not fully understood. The much
larger interstitial space present in the cell culture (compared
to solid tissues) represents a much larger H+ pool, which
leads to a pronounced H+ influx into the cells that cannot be
compensated by the cells’ active proton pumps. In solid
tissues, the extracellular H+ pool is smaller so that the cells
may be capable of maintaining their intracellular pH at a
constant level.
Whether intracellular pH plays any role at all in the
acidosis-induced decrease of calcium level also needs to
be considered. As shown in Figure 4, intracellular free Ca2+
changes occurring in response to an alteration in extracellu-
lar pH take place over a time span that is shorter than that
required for changes in intracellular pH to be seen. For this
reason, it seems unlikely that Ca2+ changes are mediated by
alterations in intracellular pH. If intracellular Ca2+ level is
independent of intracellular pH (but nevertheless dependent
on extracellular H+ level), the mechanism shown in Figure 7
may still be valid in vivo. To test such a hypothesis, however,
in vivo experiments would be necessary.
In conclusion, the present study clearly shows that an
acidic extracellular microenvironment (which is commonly
found in human tumors due to their obligatory glycolytic me-
tabolism) has an impact on the functional activity of pGP.
Under these conditions, the pGP transport rate is signifi-
cantly increased, thus leading to a lower concentration of
chemotherapeutic drugs in tumor cells and subsequently to
reduced cytotoxic efficacy. These findings may be of signifi-
cance for clinical oncology because an alleviation of extra-
cellular acidity by supportive treatments could provide a
means of increasing the chemosensitivity of tumor cells.
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